Global trends for drug-device combination product regulation are moving toward an integrated approach, shifting away from quality systems that prioritise just one component of the combination. From integrated quality sy...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
It’s complicated! When APAC global ambition meets regulatory reality
While not all sponsors plan to market treatments beyond the country of origin, many do. Those sponsors with global ambitions must decide which regulatory route offers the most strategic advantages and which market, particularly between the EU and US.
-
June 2026 Medical/Commercial Pulse Check
With the first EU JCAs finalized and CMS extending deadlines for its ambitious Medicaid international-pricing model, ICON and other industry leaders share how they are navigating the friction between global harmonization and local execution including the practical evolution of global pricing floors, the maturing role of AI agents, and the new reality of European access.
-
When your CRO’s AI platform upgrades, who pays for the change management?
This article examines the operations and cost considerations of ICON’s AI platform evolution, following it’s partnership with Microsoft to scale the Orbis platform across clinical trials.
-
ICON names Microsoft tech partner as Q1 results grow analyst confidence
This article reports on ICON naming Microsoft as a technology partner to scale its Orbis AI platform, while highlighting growing analyst confidence driven by improving performance and demand.
-
Biosimilar Success in an Evolving Landscape: Development Considerations for Staying Competitive
Regulatory pathways for biosimilars are changing, with reduced clinical requirements placing greater emphasis on analytical comparability and manufacturing excellence. Understanding how to respond to these shifts can make the difference between speed to market and costly delays. Explore the key considerations shaping today’s biosimilars landscape in ICON's latest article.
-
ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
This podcast discusses ICON’s selection of Microsoft as a preferred technology partner to scale its agentic AI platform across the clinical trial lifecycle.
-
ICON selects Microsoft to power AI-enabled clinical development
This article reports on ICON’s selection of Microsoft as a preferred technology Partner, bringing Microsoft 365 Copilot, Azure, and AI infrastructure to scale its Orbis Platform and enable AI-driven clinical development.
-
ICON selects Microsoft as preferred technology partner to scale agentic AI platform across clinical trial lifecycle
This article reports on an enterprise-wide partnership that brings Microsoft 365 Copilot, Azure, and Fabric infrastructure to ICON's Orbis platform, supporting AI deployment across study design, site operations, and regulatory workflows.
-
From automation to autonomy: How agentic AI is redefining biopharma's digital workforce
This article will explore the emerging architecture of agentic AI in biopharma: what distinguishes agents from traditional rules-based automation, how multi-agent systems orchestrate work across fragmented environments, and why strong governance and upskilled teams are essential to preventing “black-box” operational drift.
-
Liquid biopsy and the future of tumour-agnostic treatments
Explore how liquid biopsy is reshaping oncology and paving the way for truly tumour‑agnostic therapies. Read the latest insights on what this shift could mean for drug development and patient care.
